circus theme outfit

COLORADO SPRINGS, Colo. (AP) — Ethan Taylor's 21 points helped Air Force defeat Mercyhurst 82-48 on Sunday night. Taylor added 10 rebounds for the Falcons (2-4). Wesley Celichowski scored 14 points, going 6 of 11 and 2 of 3 from the free-throw line. Luke Kearney had 12 points and shot 4 for 5 from beyond the arc. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.97/iStock via Getty Images Colgate-Palmolive Company's ( NYSE: CL ) stock is usually associated with low volatility and slow and steady shareholder returns. This year, however, would go down in history as a rather unusual one as far as share price returns are considered. Until Looking for similarly well-positioned high quality businesses in the consumer staples space? You can gain access to my highest conviction ideas in the sector by subscribing to The Roundabout Investor , where I uncover conservatively priced businesses with superior competitive positioning and high dividend yields. As part of the service I also offer in-depth market analysis , through the lens of factor investing and a watchlist of higher risk-reward investment opportunities . To learn more and gain access to the service, follow the link provided. Vladimir Dimitrov, CFA is a former strategy consultant within the field of brand and intangible assets valuation. During his career in the City of London he has been working with some of the largest global brands within the technology, telecom and banking sectors. He graduated from the London School of Economics and is interested in finding reasonably priced businesses with sustainable long-term competitive advantages. The Roundabout Investor Learn more Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Please do your own due diligence and consult with your financial advisor, if you have one, before making any investment decisions. The author is not acting in an investment adviser capacity. The author's opinions expressed herein address only select aspects of potential investment in securities of the companies mentioned and cannot be a substitute for comprehensive investment analysis. The author recommends that potential and existing investors conduct thorough investment research of their own, including a detailed review of the companies' SEC filings. Any opinions or estimates constitute the author's best judgment as of the date of publication and are subject to change without notice. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX

CHICAGO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (the “Company”) (NASDAQ: MRCC) announced today that its Board of Directors has declared a distribution of $0.25 per share for the fourth quarter of 2024, payable on December 30, 2024 to stockholders of record as of December 16, 2024. In October 2012, the Company adopted a dividend reinvestment plan that provides for reinvestment of distributions on behalf of its stockholders, unless a stockholder elects to receive cash prior to the record date. When the Company declares a cash distribution, stockholders who have not opted out of the dividend reinvestment plan prior to the record date will have their distribution automatically reinvested in additional shares of the Company’s capital stock. The specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company’s periodic report filed with the Securities and Exchange Commission. About Monroe Capital Corporation Monroe Capital Corporation is a publicly-traded specialty finance company that principally invests in senior, unitranche and junior secured debt and, to a lesser extent, unsecured debt and equity investments in middle-market companies. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. The Company’s investment activities are managed by its investment adviser, Monroe Capital BDC Advisors, LLC, which is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and an affiliate of Monroe Capital LLC. To learn more about Monroe Capital Corporation, visit www.monroebdc.com . About Monroe Capital LLC Monroe Capital LLC (including its subsidiaries and affiliates, together “Monroe”) is a premier asset management firm specializing in private credit markets across various strategies, including direct lending, technology finance, venture debt, alternative credit, structured credit, real estate and equity. Since 2004, the firm has been successfully providing capital solutions to clients in the U.S. and Canada. Monroe prides itself on being a value-added and user-friendly partner to business owners, management, and both private equity and independent sponsors. Monroe’s platform offers a wide variety of investment products for both institutional and high net worth investors with a focus on generating high quality “alpha” returns irrespective of business or economic cycles. The firm is headquartered in Chicago and maintains 10 offices throughout the United States and Asia. Monroe has been recognized by both its peers and investors with various awards including Inc.'s 2024 Founder-Friendly Investors List; Private Debt Investor as the 2023 Lower Mid-Market Lender of the Decade, 2023 Lower Mid-Market Lender of the Year, 2023 CLO Manager of the Year, Americas; Global M&A Network as the 2023 Lower Mid-Markets Lender of the Year, U.S.A.; DealCatalyst as the 2022 Best CLO Manager of the Year; Korean Economic Daily as the 2022 Best Performance in Private Debt – Mid Cap; Creditflux as the 2021 Best U.S. Direct Lending Fund; and Pension Bridge as the 2020 Private Credit Strategy of the Year. For more information and important disclaimers, please visit www.monroecap.com . Forward-Looking Statements This press release may contain certain forward-looking statements. Any such statements, other than statements of historical fact, are likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under the Company’s control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from these estimates and projections of the future. Such statements speak only as of the time when made, and the Company undertakes no obligation to update any such statement now or in the future. SOURCE: Monroe Capital CorporationBiden administration officials said Wednesday they have no current plans to authorize a stockpiled bird flu vaccine , despite an escalating outbreak among livestock in the U.S. and at least 58 human infections across seven states. The move means any decisions about a bird flu vaccine will likely be left to health officials in the incoming Trump administration, who may be led by anti-vaccine activist Robert F. Kennedy Jr., whom Trump has picked to lead the Department of Health and Human Services . The virus has been spreading in dairy cows since the spring and has infected at least 774 herds in 16 states as of Wednesday, according to the Centers for Disease Control and Prevention . Last Friday, the Department of Agriculture stepped up its response to the outbreak, issuing a federal order mandating testing of the national milk supply. The USDA said the testing , set to begin next week in six states, will give farmworkers better confidence in the safety of their animals and their ability to protect themselves from infection, as well as give officials a better sense of where herds are infected. The virus’s spread in mammals that have close contact with humans is concerning for public health experts, because it gives the bird flu many opportunities to jump to people and potentially mutate to spread effectively from person to person. Almost all bird flu cases in the U.S. have been in farmworkers who have had contact with infected animals — either dairy cows or poultry — aside from a patient in Missouri and a child in California. A teen in Canada who got very sick and was hospitalized also had no clear contact with infected animals. The federal government has two bird flu vaccine candidates available in limited quantities in the nation’s Strategic National Stockpile , though they need to be authorized by the Food and Drug Administration before they can be used. In May, health officials said the government would begin looking at vaccination if the virus mutated in ways that would make existing antivirals like Tamiflu less effective, or if it appeared it was causing serious illness in people. Dr. Nirav Shah, the CDC’s principal deputy director, said Wednesday that the criteria for deploying a vaccine remains the same. “When we think about respiratory vaccines, their sweet spot is really in preventing severe disease and death,” Shah said. “When we look at what is currently unfolding with H5, even in the human cases, thankfully what we’ve seen thus far is mild disease,” he said, using a shorthand for the strain of the influenza virus causing the bird flu outbreak. “That is not a guarantee, and that could change, but that is one of the things that we are on the lookout for because the vaccine would be maximally effective against reducing severity of disease,” Shah said. While the administration isn’t considering a vaccine today, that could change if the outbreak changes, he said. Still, some public health experts believe the time for vaccination is now, particularly for farmworkers. “I do not think we should gamble with farmworkers’ lives by waiting for them to be hospitalized or die before using the tools we have to protect them,” said Jennifer Nuzzo, director of the Pandemic Center at Brown University School of Public Health. A balancing act Whether to authorize or deploy a vaccine is a constant balancing act for public health agencies, Shah said, noting that even the safest vaccine can come with side effects. In 1976, at the first signs of an H1N1 swine flu outbreak in the U.S., public health officials quickly initiated a nationwide vaccine campaign . The shot, however, caused a small increased risk of Guillain-Barre syndrome, a rare condition that causes the immune system to attack healthy nerve cells. The outbreak never spread widely, but it set public trust in the flu shot back decades. “It led to an analysis and introspection about whether the response to those 13 cases of swine flu had been an overreaction,” Shah said. “And, indeed, there was a high degree of vaccine skepticism that emerged.” Still, the public health agencies are prepared to authorize a vaccine for bird flu if needed, Shah said, adding officials are consistently testing strains against the vaccine candidates. A spokesperson at the Administration for Strategic Preparedness and Response, an agency within HHS that manages the Strategic National Stockpile, said the agency has worked to “fill and finish” vaccine doses of a candidate vaccine that’s well-matched to the virus circulating in dairy cows. There will be up to 10 million doses available by the end of the first quarter of next year, enough to vaccinate 5 million people, the spokesperson said. A spokesperson for the FDA said the agency is “actively engaged with federal partners in the U.S., as well as industry,” including evaluating potential vaccine candidates, should the need arise for use in people. When is the right time? Dr. William Schaffner, an infectious diseases expert at Vanderbilt University Medical Center, said there isn’t a need to authorize a vaccine at this time, given the lack of evidence of human-to-human spread nor signs that the virus is causing severe disease in people. Existing tools, such as antivirals and personal protective equipment, are sufficient enough right now, he said. There are a higher number of cases, but Schaffner attributed that to public health officials looking harder for the virus through testing and surveillance. Schaffner said the incoming Trump administration’s anti-vaccine rhetoric doesn’t change his stance. “I think we should be very careful about anticipating what the new administration will do,” he said. “The administration will be getting a lot of good, solid scientific evidence, not only from people at the CDC and the Food and Drug Administration, but they will hear from industry and lots of public health officials and experts across the country.” The Trump transition team didn’t respond to a request for comment. Dr. Keith Poulsen, director of the Wisconsin Veterinary Diagnostic Laboratory, also said it’s not necessary to authorize a vaccine at this time. “We need to keep advocating based on the science and data to make informed decisions, or do the best we can at the intersection of science, economics and political science,” Poulsen said. Nuzzo, of the Brown University School of Public Health, said that while antivirals are important for anyone exposed to or infected with the virus, their effectiveness is limited by a very small window of time in which they must be given. She also said the country’s testing strategy is not timely enough to adequately protect farmworkers. A vaccine, she said, could protect farmworkers from the possibility of severe illness. Poulsen said one issue officials could run into, however, is finding farmworkers who are willing to get the vaccine, noting that some may be distrustful of the shot. “I would start with seasonal flu and only go to the H5N1 strains if they find that people are propagating virus or getting severely sick,” Poulsen said. “That has not happened.”